



May 9, 2022

Adimab Announces Promotions of New Chief Executive Officer and President

- *Philip T. Chase promoted to Chief Executive Officer -*
- *Dr. Eric M. Krauland named President as well as Chief Scientific Officer -*
- *Co-Founder Tillman Gerngross assumes new role as Executive Chairman of the Board -*

Lebanon, New Hampshire – May 9, 2022 - Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced the appointments of Philip T. Chase as Chief Executive Officer and Eric M. Krauland as President and Chief Scientific Officer. Mr. Chase has been serving as Adimab’s General Counsel for more than ten years and Dr. Krauland has held a variety of leadership positions at Adimab since 2007, including serving as Adimab’s Chief Scientific Officer since 2017. After 15 years, former CEO and Co-Founder Tillman U. Gerngross will step away from day-to-day operations at Adimab and move to a strategic role as Executive Chairman of the Board.

“Adimab has been the crown jewel of my professional and entrepreneurial endeavors and I feel we have made a remarkable impact as a company. I have the utmost confidence in this leadership team, who has been executing together for more than a decade, and I am proud to offer them this growth opportunity,” said Dr. Gerngross.

“This next generation of management is committed to carrying forward Adimab’s well-established business model,” stated Mr. Chase. “We look forward to continuing to provide the highest quality therapeutic antibodies to our many current and future partners.”

About Philip T. Chase

Prior to Adimab, Mr. Chase held positions at various biotechnology companies, including serving as the General Counsel at Alnylam Pharmaceuticals and as Chief Corporate Counsel at Transkaryotic Therapies, Inc. Prior to moving into the biotechnology industry, Mr. Chase worked at the law firms of Skadden, Arps, Slate, Meagher & Flom LLP and Shearman & Sterling LLP. He received his J.D. degree from Columbia University School of Law and his B.A. from Colby College.

About Eric M. Krauland

Dr. Krauland began his career at Adimab in 2007 shortly after the founding of the company and was named Chief Scientific Officer in 2017. Dr. Krauland was a key contributor in the development of Adimab's antibody discovery and optimization technology. He received his Ph.D. degree from the Massachusetts Institute of Technology and his B.S./M.S.E. from Johns Hopkins University.

About Adimab

Adimab is the leading provider of therapeutic antibody discovery and engineering technologies. This includes naïve discovery from synthetic libraries in yeast or B cells (mice, camelid, and humans), antibody engineering and optimization, multi-specific antibody engineering, and a portfolio of proprietary CD3 antibodies licensed non-exclusively for bispecific applications. Adimab focuses solely on its partners and not on developing an internal product pipeline. Since 2009, Adimab has partnered with 100 pharmaceutical and biotechnology companies, generating more than 435 therapeutic programs, 56 clinical programs, and its first approved product. The Adimab technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, Novo Nordisk, and Takeda. Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Regeneron, Sanofi, Takeda and others. Adimab has also partnered with many early-stage venture-backed companies, including Amagma, Cygnal, Dragonfly, iOmx, NextPoint, Pliant, Tizona, TRex Bio and others, as well as mid-size public biopharmaceutical companies such as Acceleron, Alector, Cullinan Oncology, Innovent, Jounce, Mersana, Scholar Rock, Surface Oncology, and others.

Adimab's integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit <http://www.adimab.com>.

Guy Van Meter
Chief Business Officer
Adimab, LLC.
(603) 653-5775
guy.vanmeter@adimab.com